first dose of Shingrix in 2018. He did not know that he needed a second dose at the time; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose in 2018). On 09-JAN-2025, the patient received the 2nd dose of Shingrix. On 09-JAN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: first dose of Shingrix in 2018. He did not know that he needed a second dose at the time). The outcome of the drug dose administration interval too long was unknown. Additional Information: GSK Receipt Date: 09-JAN-2025 The reporter was the patient who received his first dose of Shingrix in 2018. The patient did not know that he needed a second dose at the time. The patient received his second dose on the day of reporting which led to lengthening of vaccination schedule.